<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiovascular</journal-id><journal-title-group><journal-title xml:lang="ru">Кардиоваскулярная терапия и профилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Cardiovascular Therapy and Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1728-8800</issn><issn pub-type="epub">2619-0125</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1728-8800-2023-3547</article-id><article-id custom-type="elpub" pub-id-type="custom">cardiovascular-3547</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>АРТЕРИАЛЬНАЯ ГИПЕРТОНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ARTERIAL HYPERTENSION</subject></subj-group></article-categories><title-group><article-title>Приверженность к лечению и ее роль в решении проблемы неконтролируемой артериальной гипертензии</article-title><trans-title-group xml:lang="en"><trans-title>Compliance to treatment and its role in solving the problem of uncontrolled hypertension</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0758-5609</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Подзолков</surname><given-names>В. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Podzolkov</surname><given-names>V. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Подзолков Валерий Иванович — профессор, доктор медицинских наук, заведующий кафедрой факультетской терапии № 2 Института клинической медицины, директор клиники факультетской терапии УКБ № 4.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">podzolkov@list.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2699-1610</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Брагина</surname><given-names>А. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Bragina</surname><given-names>A. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Брагина Анна Евгеньевна — доктор медицинских наук, профессор кафедры факультетской терапии № 2 Института клинической медицины.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">anna.bragina@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4210-2841</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Медведев</surname><given-names>И. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Medvedev</surname><given-names>I. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Медведев Иван Дмитриевич — кандидат медицинских наук, доцент кафедры факультетской терапии № 2 Института клинической медицины.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">ivanmedvedev_123@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9733-4813</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ветлужская</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Vetluzhskaya</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ветлужская Мария Владимировна — кандидат медицинских наук, доцент кафедры факультетской терапии № 2 Института клинической медицины.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">maria.vetluzhskaya@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3311-6072</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Абрамова</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Abramova</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Абрамова Антонина Аркадьевна — кандидат медицинских наук, доцент кафедры факультетской терапии № 2 Института клинической медицины.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">antonina814@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8908-7381</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лория</surname><given-names>И. Ж.</given-names></name><name name-style="western" xml:lang="en"><surname>Loria</surname><given-names>I. Zh.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лория Иракли Жанович — кандидат медицинских наук, доцент кафедры факультетской терапии № 2 Института клинической медицины.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">lordoc7@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6667-4257</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мегенеишвили</surname><given-names>Н. К.</given-names></name><name name-style="western" xml:lang="en"><surname>Megeneishvili</surname><given-names>N. K.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мегенеишвили Нино Кахабериевна — студентка Института клинической медицины.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">nino.megeneishvili@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3321-0445</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сутулова</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Sutulova</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сутулова Ангелина Викторовна — студентка Института клинической медицины.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">angelina.sutulova@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГАОУ ВО "Первый Московский государственный медицинский университет им. И.М. Сеченова" Минздрава России (Сеченовский университет)</institution></aff><aff xml:lang="en"><institution>I.M. Sechenov First Moscow State Medical University</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>08</day><month>05</month><year>2023</year></pub-date><volume>22</volume><issue>4</issue><fpage>3547</fpage><lpage>3547</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Подзолков В.И., Брагина А.Е., Медведев И.Д., Ветлужская М.В., Абрамова А.А., Лория И.Ж., Мегенеишвили Н.К., Сутулова А.В., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Подзолков В.И., Брагина А.Е., Медведев И.Д., Ветлужская М.В., Абрамова А.А., Лория И.Ж., Мегенеишвили Н.К., Сутулова А.В.</copyright-holder><copyright-holder xml:lang="en">Podzolkov V.I., Bragina A.E., Medvedev I.D., Vetluzhskaya M.V., Abramova A.A., Loria I.Z., Megeneishvili N.K., Sutulova A.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://cardiovascular.elpub.ru/jour/article/view/3547">https://cardiovascular.elpub.ru/jour/article/view/3547</self-uri><abstract><p>Недостижение целевых показателей артериального давления и недостаточный контроль — важные проблемы кардиологии, сохраняющие свою актуальность, несмотря на четко сформулированные и общедоступные современные алгоритмы лечения артериальной гипертензии (АГ) и наличие эффективных антигипертензивных препаратов с обширной доказательной базой. Уровень контроля АГ в России остается довольно низким и составляет 14,1% для мужчин и 30,9% для женщин. Общепризнанным важнейшим фактором, определяющим низкий уровень контроля артериального давления, является несоблюдение приверженности к антигипертензивной терапии, что, в свою очередь, определяет высокий процент неконтролируемой АГ среди пациентов. В обзоре обсуждаются наиболее частые причины низкой приверженности к лечению. Особенное внимание уделено возможностям врача устранять барьеры на пути к достижению приверженности и ошибкам при выборе терапии, в т.ч. и недостаточное назначение фиксированных комбинаций препаратов. В обзоре изложен современный взгляд на значимость комбинированной антигипертензивной терапии в лечении АГ. Акцентируется внимание на фиксированных комбинациях антигипертензивных препаратов, применение которых существенно повышает приверженность к терапии, а также описываются уникальные свойства и эффективность лизиноприла, амлодипина и индапамида.</p></abstract><trans-abstract xml:lang="en"><p>Failure to achieve blood pressure targets and insufficient control are important cardiology problems that remain relevant despite well-defined and generally available modern algorithms for the treatment of hypertension (HTN) and the availability of effective antihypertensive drugs. The level of hypertension control in Russia remains quite low and is 14,1% for men and 30,9% for women. The generally recognized most important factor determining the low blood pressure control is non-compliance with antihypertensive therapy, which, in turn, determines the high percentage of uncontrolled HTN among patients. The review discusses the most common causes of low adherence to treatment. Particular attention is paid to the doctor’s ability to remove barriers to adherence and errors in the choice of therapy, including insufficient prescribing of fixed-dose combinations. The review presents a modern view on the significance of combined antihypertensive therapy. Atten­tion is focused on fixed-dose combinations of antihypertensives, the use of which significantly increases adherence to therapy, and the unique properties and effectiveness of lisinopril, amlodipine and indapamide are described.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>артериальная гипертензия</kwd><kwd>приверженность</kwd><kwd>фиксированная комбинация</kwd><kwd>индапамид</kwd><kwd>амлодипин</kwd><kwd>лизиноприл</kwd></kwd-group><kwd-group xml:lang="en"><kwd>hypertension</kwd><kwd>adherence</kwd><kwd>fixed-dose combination</kwd><kwd>indapa­mide</kwd><kwd>amlodipine</kwd><kwd>lisinopril</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Публикация данной статьи поддержана компанией Гедеон Рихтер, что не повлияло на собственное мнение авторов.</funding-statement><funding-statement xml:lang="en">The publication of this article was sup­ported by Gedeon Richter, which did not affect the authors’ own opinion.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 popu­lation-representative studies with 104 million participants. Lancet. 2021;398(10304):957-80. doi:10.1016/S0140-6736(21)01330-1.</mixed-citation><mixed-citation xml:lang="en">NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 popu­lation-representative studies with 104 million participants. Lancet. 2021;398(10304):957-80. doi:10.1016/S0140-6736(21)01330-1.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Бойцов С. А., Баланова Ю. А., Шальнова С. А. и др. Артериальная гипертония среди лиц 25-64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваскулярная терапия и профилактика. 2014;13(4):4-14. doi:10.15829/1728-8800-2014-4-4-14.</mixed-citation><mixed-citation xml:lang="en">Boytsov SA, Balanova YuA, Shalnova SA, et al. Arterial hyper­tension among individuals of 25-64 years old: prevalence, awareness, treatment and control. By The Data from ECCD. Cardiovascular Therapy and Prevention. 2014;13(4):4-14. (In Russ.) doi:10.15829/1728-8800-2014-4-4-14.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Tsao CW, Aday AW, Almarzooq ZI, et al. Heart Disease and Stroke Statistics — 2023 Update: A Report from the American Heart Association. Circulation. Circulation. 2023;147:e93-e621. doi:10.1161/CIR.0000000000001123.</mixed-citation><mixed-citation xml:lang="en">Tsao CW, Aday AW, Almarzooq ZI, et al. Heart Disease and Stroke Statistics — 2023 Update: A Report from the American Heart Association. Circulation. Circulation. 2023;147:e93-e621. doi:10.1161/CIR.0000000000001123.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Weldegiorgis M, Woodward M. The impact of hypertension on chronic kidney disease and end-stage renal disease is greater in men than women: a systematic review and meta-analysis. BMC Nephrol. 2020;21:506. doi:10.1186/s12882-020-02151-7.</mixed-citation><mixed-citation xml:lang="en">Weldegiorgis M, Woodward M. The impact of hypertension on chronic kidney disease and end-stage renal disease is greater in men than women: a systematic review and meta-analysis. BMC Nephrol. 2020;21:506. doi:10.1186/s12882-020-02151-7.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou Y, Yang Q, Chi J, et al. Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: A systematic review and meta-analysis. Int J Infect Dis. 2020;99:47-56. doi:10.1016/j.ijid.2020.07.029.</mixed-citation><mixed-citation xml:lang="en">Zhou Y, Yang Q, Chi J, et al. Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: A systematic review and meta-analysis. Int J Infect Dis. 2020;99:47-56. doi:10.1016/j.ijid.2020.07.029.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Williams B, Mancia G, Spiering W, et al. 2018 Practice Gui­delines for the management of arterial hypertension of the Euro­pean Society of Hypertension and the European Society of Cardio­logy: ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens. 2018;36(12):2284-309. doi:10.1093/eurheartj/ehy339.</mixed-citation><mixed-citation xml:lang="en">Williams B, Mancia G, Spiering W, et al. 2018 Practice Gui­delines for the management of arterial hypertension of the Euro­pean Society of Hypertension and the European Society of Cardio­logy: ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens. 2018;36(12):2284-309. doi:10.1093/eurheartj/ehy339.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Кобалава Ж. Д., Конради А. О., Недогода С. В. и др. Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(3):3786. doi:10.15829/1560-4071-2020-3-3786.</mixed-citation><mixed-citation xml:lang="en">Kobalava ZD, Konradi AO, Nedogoda SV, et al. Arterial hyper­tension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. (In Russ.) doi:10.15829/1560-4071-2020-3-3786.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Burnier M, Egan BM. Adherence in Hypertension. Circ Res. 2019;124(7):1124-40. doi:10.1161/CIRCRESAHA.118.313220.</mixed-citation><mixed-citation xml:lang="en">Burnier M, Egan BM. Adherence in Hypertension. Circ Res. 2019;124(7):1124-40. doi:10.1161/CIRCRESAHA.118.313220.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Abegaz TM, Shehab A, Gebreyohannes EA, et al. Nonadherence to antihypertensive drugs: A systematic review and meta-analysis. Medicine (Baltimore). 2017;96(4):e5641. doi:10.1097/MD.0000000000005641.</mixed-citation><mixed-citation xml:lang="en">Abegaz TM, Shehab A, Gebreyohannes EA, et al. Nonadherence to antihypertensive drugs: A systematic review and meta-analysis. Medicine (Baltimore). 2017;96(4):e5641. doi:10.1097/MD.0000000000005641.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Подзолков В. И., Брагина А. Е., Наткина Д. У. и др. Состояние сосудистой стенки и параметры микроциркуляции при конт­ролируемой и неконтролируемой артериальной гипертензии. Рациональная Фармакотерапия в Кардиологии. 2019;15(4):495-501. doi:10.20996/1819-6446-2019-15-4-495-501.</mixed-citation><mixed-citation xml:lang="en">Podzolkov VI, Bragina AE, Natkina DU, et al. The Vascular Wall State and Microcirculation Parameters in Patients with Controlled and Uncontrolled Arterial Hypertension. Rational Pharmacotherapy in Cardiology. 2019;15(4):495-501. (In Russ.) doi:10.20996/1819-6446-2019-15-4-495-501.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Подзолков В. И., Брагина А. Е., Наткина Д. У. и др. Сосудистые маркеры когнитивной дисфункции у пациентов с неконтролируемой артериальной гипертензией. Сеченовский вестник. 2020;11(3):26-36. doi:10.47093/2218-7332.2020.11.3.26-36.</mixed-citation><mixed-citation xml:lang="en">Podzolkov VI, Bragina AE, Natkina DU, et al. Vascular markers of cognitive dysfunction in patients with uncontrolled arterial hypertension. Sechenov Medical Journal. 2020;11(3):26-36. (In Russ.) doi:10.47093/2218-7332.2020.11.3.26-36.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">World Health Organization. Adherence to Long Term Therapies: Evidence for Action; Geneva: World Health Organization, 2003. ISBN: 9241545992.</mixed-citation><mixed-citation xml:lang="en">World Health Organization. Adherence to Long Term Therapies: Evidence for Action; Geneva: World Health Organization, 2003. ISBN: 9241545992.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Шальнова С. А., Конради А. О., Баланова Ю. А. и др. Какие факторы влияют на контроль артериальной гипертонии в России. Кардиоваскулярная терапия и профилактика. 2018;17(4):53-60. doi:10.15829/1728-8800-2018-4-53-60.</mixed-citation><mixed-citation xml:lang="en">Shalnova SA, Konradi AО, Balanova YuA, et al. What factors do influence arterial hypertension control in Russia. Cardiovascular Therapy and Prevention. 2018;17(4):53-60. (In Russ.) doi:10.15829/1728-8800-2018-4-53-60.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Lee EKP, Poon P, Yip BHK, et al. Global Burden, Regional Dif­ferences, Trends, and Health Consequences of Medication Nonadherence for Hypertension During 2010 to 2020: A Meta-Analysis Involving 27 Million Patients. J Am Heart Assoc. 2022;11(17):e026582. doi:10.1161/JAHA.122.026582.</mixed-citation><mixed-citation xml:lang="en">Lee EKP, Poon P, Yip BHK, et al. Global Burden, Regional Dif­ferences, Trends, and Health Consequences of Medication Nonadherence for Hypertension During 2010 to 2020: A Meta-Analysis Involving 27 Million Patients. J Am Heart Assoc. 2022;11(17):e026582. doi:10.1161/JAHA.122.026582.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Aitini E, Martignoni G, Labianca R, et al. Communication Models for Doctor-Patient Relationships. J Canc Educ. 2014;29:211-2. doi:10.1007/s13187-014-0616-z.</mixed-citation><mixed-citation xml:lang="en">Aitini E, Martignoni G, Labianca R, et al. Communication Models for Doctor-Patient Relationships. J Canc Educ. 2014;29:211-2. doi:10.1007/s13187-014-0616-z.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Mallia P. The Nature of the Doctor-Patient Relationship. Health Care Principles Through the Phenomenology of Relationships with Patients. Springer. 2013. ISSN 2211-8101. ISBN: 978-94-007-4938-2. doi:10.1007/978-94-007-4939-9.</mixed-citation><mixed-citation xml:lang="en">Mallia P. The Nature of the Doctor-Patient Relationship. Health Care Principles Through the Phenomenology of Relationships with Patients. Springer. 2013. ISSN 2211-8101. ISBN: 978-94-007-4938-2. doi:10.1007/978-94-007-4939-9.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Vrijens B, Antoniou S, Burnier M, et al. Current Situation of Me­dication Adherence in Hypertension. Front Pharmacol. 2017;8:100. doi:10.3389/fphar.2017.00100.</mixed-citation><mixed-citation xml:lang="en">Vrijens B, Antoniou S, Burnier M, et al. Current Situation of Me­dication Adherence in Hypertension. Front Pharmacol. 2017;8:100. doi:10.3389/fphar.2017.00100.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Dalal JJ, Kerkar P, Guha S, et al. Therapeutic adherence in hypertension: Current evidence and expert opinion from India. Indian Heart J. 2021;73(6):667-73. doi:10.1016/j.ihj.2021.09.003.</mixed-citation><mixed-citation xml:lang="en">Dalal JJ, Kerkar P, Guha S, et al. Therapeutic adherence in hypertension: Current evidence and expert opinion from India. Indian Heart J. 2021;73(6):667-73. doi:10.1016/j.ihj.2021.09.003.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):1269-1324. doi:10.1161/HYP.0000000000000066.</mixed-citation><mixed-citation xml:lang="en">Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):1269-1324. doi:10.1161/HYP.0000000000000066.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Подзолков В. И., Брагина А. Е., Осадчий К. К. Резистентная гипертензия: вопросы и современные ответы. Рациональная Фармакотерапия в Кардиологии. 2019;15(4):568-77. doi:10.20996/1819-6446-2019-15-4-568-577.</mixed-citation><mixed-citation xml:lang="en">Podzolkov VI, Bragina AE, Osadchiy KK. Resistant Hyper­tension: Questions and Contemporary Answers. Rational Pharmacotherapy in Cardiology 2019;15(4):568-77. (In Russ.) doi:10.20996/1819-6446-2019-15-4-568-577.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Parati G, Lombardi C, Pengo M, et al Current challenges for hypertension management: From better hypertension diagnosis to improved patients’ adherence and blood pressure control. Intern J Cardiol. 2021;331:262-9. doi:10.1016/j.ijcard.2021.01.070.</mixed-citation><mixed-citation xml:lang="en">Parati G, Lombardi C, Pengo M, et al Current challenges for hypertension management: From better hypertension diagnosis to improved patients’ adherence and blood pressure control. Intern J Cardiol. 2021;331:262-9. doi:10.1016/j.ijcard.2021.01.070.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Gupta P, Patel P, Štrauch B, et al. Biochemical Screening for Nonadherence Is Associated With Blood Pressure Reduction and Improvement in Adherence. Hypertension. 2017;70(5):1042-8. doi:10.1161/HYPERTENSIONAHA.117.09631.</mixed-citation><mixed-citation xml:lang="en">Gupta P, Patel P, Štrauch B, et al. Biochemical Screening for Nonadherence Is Associated With Blood Pressure Reduction and Improvement in Adherence. Hypertension. 2017;70(5):1042-8. doi:10.1161/HYPERTENSIONAHA.117.09631.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Hagendorff A, Freytag S, Müller A, et al. Pill burden in hyper­tensive patients treated with single-pill combination therapy — an observational study. Adv Ther. 2013;30(4):406-19. doi:10.1007/s12325-013-0018-3.</mixed-citation><mixed-citation xml:lang="en">Hagendorff A, Freytag S, Müller A, et al. Pill burden in hyper­tensive patients treated with single-pill combination therapy — an observational study. Adv Ther. 2013;30(4):406-19. doi:10.1007/s12325-013-0018-3.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Jamerson K, Weber MA, Bakris GL, et al. ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417-28. doi:10.1056/NEJMoa0806182.</mixed-citation><mixed-citation xml:lang="en">Jamerson K, Weber MA, Bakris GL, et al. ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417-28. doi:10.1056/NEJMoa0806182.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Parati G, Kjeldsen S, Coca A, et al. Adherence to Single-Pill Versus Free-Equivalent Combination Therapy in Hypertension. A Systematic Review and Meta-Analysis. Hypertension. 2021;77(2):692-705. doi:10.1161/HYPERTENSIONAHA.120.15781.</mixed-citation><mixed-citation xml:lang="en">Parati G, Kjeldsen S, Coca A, et al. Adherence to Single-Pill Versus Free-Equivalent Combination Therapy in Hypertension. A Systematic Review and Meta-Analysis. Hypertension. 2021;77(2):692-705. doi:10.1161/HYPERTENSIONAHA.120.15781.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Jaffe MG, Lee GA, Young JD, et al. Improved blood pressure control associated with a large-scale hypertension program. JAMA. 2013;310(7):699-705. doi:10.1001/jama.2013.108769.</mixed-citation><mixed-citation xml:lang="en">Jaffe MG, Lee GA, Young JD, et al. Improved blood pressure control associated with a large-scale hypertension program. JAMA. 2013;310(7):699-705. doi:10.1001/jama.2013.108769.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Kizilirmak P, Berktas M, Uresin Y, et al. The efficacy and safety of triple vs dual combination of angiotensin II receptor blocker and calcium channel blocker and diuretic: a systematic review and meta-analysis. J Clin Hypertens (Greenwich). 2013;15(3):193-200. doi:10.1111/jch.12040.</mixed-citation><mixed-citation xml:lang="en">Kizilirmak P, Berktas M, Uresin Y, et al. The efficacy and safety of triple vs dual combination of angiotensin II receptor blocker and calcium channel blocker and diuretic: a systematic review and meta-analysis. J Clin Hypertens (Greenwich). 2013;15(3):193-200. doi:10.1111/jch.12040.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Semple PF, Cumming AM, Meredith PA, et al. Onset of action of captopril, enalapril, enalaprilic acid and lisinopril in normal man. Cardiovasc Drugs Ther. 1987;1(1):45-50. doi:10.1007/BF02125832.</mixed-citation><mixed-citation xml:lang="en">Semple PF, Cumming AM, Meredith PA, et al. Onset of action of captopril, enalapril, enalaprilic acid and lisinopril in normal man. Cardiovasc Drugs Ther. 1987;1(1):45-50. doi:10.1007/BF02125832.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Fares H, DiNicolantonio JJ, O’Keefe JH, et al. Amlodipine in hypertension: a first-line agent with efficacy for improving blood pressure and patient outcomes. Open Heart. 2016;3:e000473. doi:10.1136/openhrt-2016-000473.</mixed-citation><mixed-citation xml:lang="en">Fares H, DiNicolantonio JJ, O’Keefe JH, et al. Amlodipine in hypertension: a first-line agent with efficacy for improving blood pressure and patient outcomes. Open Heart. 2016;3:e000473. doi:10.1136/openhrt-2016-000473.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Ferrario CM. Cardiac remodelling and RAS inhibition. Ther Adv Cardiovasc Dis. 2016;10(3):162-71. doi:10.1177/1753944716642677.</mixed-citation><mixed-citation xml:lang="en">Ferrario CM. Cardiac remodelling and RAS inhibition. Ther Adv Cardiovasc Dis. 2016;10(3):162-71. doi:10.1177/1753944716642677.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Lancaster SG, Todd PA. Lisinopril. A preliminary review of its phar­macodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs. 1988;35(6):646-69. doi:10.2165/00003495-198835060-00003.</mixed-citation><mixed-citation xml:lang="en">Lancaster SG, Todd PA. Lisinopril. A preliminary review of its phar­macodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs. 1988;35(6):646-69. doi:10.2165/00003495-198835060-00003.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Langtry HD, Markham A. Lisinopril. A review of its pharmacology and clinical efficacy in elderly patients. Drugs Aging. 1997;10(2):131-66. doi:10.2165/00002512-199710020-00006.</mixed-citation><mixed-citation xml:lang="en">Langtry HD, Markham A. Lisinopril. A review of its pharmacology and clinical efficacy in elderly patients. Drugs Aging. 1997;10(2):131-66. doi:10.2165/00002512-199710020-00006.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Подзолков В. И., Тарзиманова А. И. Лизиноприл в лечении больных артериальной гипертензией. Кардиология. 2017;57(9):77-82. doi:10.18087/cardio.2017.9.10031.</mixed-citation><mixed-citation xml:lang="en">Podzolkov VI, Tarzimanova AI. Lizinopril in the Treatment of Arterial Hypertension. Kardiologiia. 2017;57(9):77-82. (In Russ.) doi:10.18087/cardio.2017.9.10031.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Mancia G, Zanchetti A, Agabiti-Rosei E, et al. Study on monitoring of blood pressure and lisinopril evaluation. Circulation. 1997; 95(6);1464-70. doi:10.1161/01.cir.95.6.1464.</mixed-citation><mixed-citation xml:lang="en">Mancia G, Zanchetti A, Agabiti-Rosei E, et al. Study on monitoring of blood pressure and lisinopril evaluation. Circulation. 1997; 95(6);1464-70. doi:10.1161/01.cir.95.6.1464.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Shimamoto H, Shimamoto Y. Lisinopril reverses left ventricular hypertrophy through improved aortic compliance. Hypertension. 1996;28(3):457-63. doi:10.1161/01.hyp.28.3.457.</mixed-citation><mixed-citation xml:lang="en">Shimamoto H, Shimamoto Y. Lisinopril reverses left ventricular hypertrophy through improved aortic compliance. Hypertension. 1996;28(3):457-63. doi:10.1161/01.hyp.28.3.457.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Hernández D, Lacalzada J, Salido E, et al. Regression of left ventricular hypertrophy by lisinopril after renal transplantation: role of ACE gene polymorphism. Kidney Int. 2000;58(2):889-97. doi:10.1046/j.1523-1755.2000.00239.x.</mixed-citation><mixed-citation xml:lang="en">Hernández D, Lacalzada J, Salido E, et al. Regression of left ventricular hypertrophy by lisinopril after renal transplantation: role of ACE gene polymorphism. Kidney Int. 2000;58(2):889-97. doi:10.1046/j.1523-1755.2000.00239.x.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Poulsen PL, Ebbehøj E, Mogensen CE. Lisinopril reduces albuminuria during exercise in low grade microalbuminuric Type 1 diabetic patients: a double blind randomized study. J Intern Med. 2001;249:433-40. doi:10.1046/j.1365-2796.2001.00821.x.</mixed-citation><mixed-citation xml:lang="en">Poulsen PL, Ebbehøj E, Mogensen CE. Lisinopril reduces albuminuria during exercise in low grade microalbuminuric Type 1 diabetic patients: a double blind randomized study. J Intern Med. 2001;249:433-40. doi:10.1046/j.1365-2796.2001.00821.x.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Scisciola L, Fontanella RA, Surina, et al. Potential Role of Lisinopril in Reducing Atherosclerotic Risk: Evidence of an Antioxidant Effect in Human Cardiomyocytes Cell Line. Front. Pharmacol. 2022;13:868365. doi:10.3389/fphar.2022.868365.</mixed-citation><mixed-citation xml:lang="en">Scisciola L, Fontanella RA, Surina, et al. Potential Role of Lisinopril in Reducing Atherosclerotic Risk: Evidence of an Antioxidant Effect in Human Cardiomyocytes Cell Line. Front. Pharmacol. 2022;13:868365. doi:10.3389/fphar.2022.868365.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Roush GC, Kaur R, Ernst ME. Diuretics: A Review and Update. J Cardiovasc Pharmacol Ther. 2014;19(1):5-13. doi:10.1177/1074248413497257.</mixed-citation><mixed-citation xml:lang="en">Roush GC, Kaur R, Ernst ME. Diuretics: A Review and Update. J Cardiovasc Pharmacol Ther. 2014;19(1):5-13. doi:10.1177/1074248413497257.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">London G. Efficacy of indapamide 1.5 mg, sustained release, in the lowering of systolic blood pressure. J Hum Hypertens. 2004;18(2):9-14. doi:10.1038/sj.jhh.1001799.</mixed-citation><mixed-citation xml:lang="en">London G. Efficacy of indapamide 1.5 mg, sustained release, in the lowering of systolic blood pressure. J Hum Hypertens. 2004;18(2):9-14. doi:10.1038/sj.jhh.1001799.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Sassard J, Bataillard A, McIntyre H. An overview of the pharma­cology and clinical efficacy of indapamide sustained release. Fundam Clin Pharmacol. 2005;19(6):637-45. doi:10.1111/j.1472-8206.2005.00377.x.</mixed-citation><mixed-citation xml:lang="en">Sassard J, Bataillard A, McIntyre H. An overview of the pharma­cology and clinical efficacy of indapamide sustained release. Fundam Clin Pharmacol. 2005;19(6):637-45. doi:10.1111/j.1472-8206.2005.00377.x.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Weidmann P. Metabolic profile of indapamide sustained-release in patients with hypertension: data from three randomised double-blind studies. Drug Saf. 2001;24(15):1155-65. doi:10.2165/00002018-200124150-00006.</mixed-citation><mixed-citation xml:lang="en">Weidmann P. Metabolic profile of indapamide sustained-release in patients with hypertension: data from three randomised double-blind studies. Drug Saf. 2001;24(15):1155-65. doi:10.2165/00002018-200124150-00006.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Wang S, Li J, Zhou X, et al. Comparison between the effects of hyd­rochlorothiazide and indapamide on the kidney in hyper­tensive patients inadequately controlled with losartan. J Hum Hypertens. 2017;31(12):848-54. doi:10.1038/jhh.2017.51.</mixed-citation><mixed-citation xml:lang="en">Wang S, Li J, Zhou X, et al. Comparison between the effects of hyd­rochlorothiazide and indapamide on the kidney in hyper­tensive patients inadequately controlled with losartan. J Hum Hypertens. 2017;31(12):848-54. doi:10.1038/jhh.2017.51.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Marre M, Puig JG, Kokot F, et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study. J Hypertens. 2004;22(8):1613-22. doi:10.1097/01.hjh.0000133733.32125.09.</mixed-citation><mixed-citation xml:lang="en">Marre M, Puig JG, Kokot F, et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study. J Hypertens. 2004;22(8):1613-22. doi:10.1097/01.hjh.0000133733.32125.09.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Beckett NS, Peters R, Fletcher AE, et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887-98. doi:10.1056/NEJMoa0801369.</mixed-citation><mixed-citation xml:lang="en">Beckett NS, Peters R, Fletcher AE, et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887-98. doi:10.1056/NEJMoa0801369.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Chalmers J, Mourad JJ, De Champvallins M, et al. Benefit of indapamide-based treatment on mortality: a systematic review and meta-analysis. J Hypertens. 2019;37:e57. doi:10.1097/01.hjh.0000570928.33807.a8.</mixed-citation><mixed-citation xml:lang="en">Chalmers J, Mourad JJ, De Champvallins M, et al. Benefit of indapamide-based treatment on mortality: a systematic review and meta-analysis. J Hypertens. 2019;37:e57. doi:10.1097/01.hjh.0000570928.33807.a8.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Meurin P. The ASCOT trial: clarifying the role of ACE inhibition in the reduction of cardiovascular events in patients with hypertension. Am J Cardiovasc Drugs. 2006;6(5):327-34. doi:10.2165/00129784-200606050-00005.</mixed-citation><mixed-citation xml:lang="en">Meurin P. The ASCOT trial: clarifying the role of ACE inhibition in the reduction of cardiovascular events in patients with hypertension. Am J Cardiovasc Drugs. 2006;6(5):327-34. doi:10.2165/00129784-200606050-00005.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Недогода С. В., Санина Т. Н., Цома В. В. и др. Оптимизация контроля артериального давления и органопротекции с помощью фиксированной комбинации лизиноприла, амлодипина и индапамида у пациентов с артериальной гипертензией. Рациональная Фармакотерапия в Кардиологии 2020;16(6):931-7. doi:10.20996/1819-6446-2020-11-03.</mixed-citation><mixed-citation xml:lang="en">Nedogoda SV, Sanina TN, Tsoma VV, et al. Optimal Organ Protection and Blood Pressure Control with the Single Pill Combination Lisinopril, Amlodipine and Indapamide in Arterial Hypertension. Rational Pharmacotherapy in Cardiology. 2020;16(6):931-7. (In Russ.) doi:10.20996/1819-6446-2020-11-03.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
